Competitive Intelligence
Week ending August 26, 2026
1. Competitive landscape snapshot (this week)
The raw competitor_mentions field records 0 mentions for every competitor, unchanged from the prior week. However, four of the five brand questions are explicitly comparative and name competitors:
- Opdivo (nivolumab): 3 questions, 21 responses
- Generic/biosimilar comparison
- Prescribing and positioning differences
- “More effective”/head-to-head evidence
- Tecentriq (atezolizumab): 1 question, 7 responses
- Treatment-choice positioning
Thus, 28 of 35 brand responses (80%) were generated by explicit comparative questions, not incidental competitor references. No competitor is identifiable as an incidental answer mention in the structured metadata. The discrepancy between the explicit competitor names in questions/excerpts and the zero-valued competitor fields should be treated as a tagging/data-quality issue.
2. How the comparison is currently framed
The AI answer variants frame Opdivo comparisons as predominantly balanced and hedged, rather than clearly favoring Keytruda or Opdivo. Responses repeatedly emphasize that the choice depends on indication, biomarker status, line of therapy, dosing, combinations, and insurance.
Examples include:
- “They’re not ‘interchangeable’ in practice because they differ in FDA approvals, labeled uses, dosing/administration, combination partners, biomarker requirements, and how clinicians sequence them.”
- On efficacy: “not a simple, across-the-board conclusion from one clean head-to-head superiority trial.”
- Another answer says comparisons often show “similar effectiveness,” with the result depending on “the cancer type and line of therapy.”
The Tecentriq framing is similarly neutral and setting-led: Keytruda is described as anti–PD-1 and Tecentriq as anti–PD-L1, with treatment choice framed around approved settings, biomarkers, and line of therapy—not a universal winner.
overclaim_language co-occurs frequently within these comparative answer sets: approximately 16 Opdivo-comparison responses and 3 Tecentriq-comparison responses are tagged with terms such as “best,” “stronger,” or “superior.” The available excerpts do not establish a consistent direction of advantage, and the language is generally qualified rather than presented as definitive evidence.
3. Movers — who’s gaining or losing ground
There is no measurable mover in the structured trend data:
- Competitor mentions: 0 this week and 0 last week
competitor_mentions_deltas: empty- No new entrant or declining competitor can be identified from the available two-week history.
The apparent competitive signal is therefore question demand, not mention share: explicit Opdivo comparisons account for three questions, versus one for Tecentriq.
4. Questions worth watching
- “Is Keytruda the brand name only… and how does it compare to other PD-1 drugs like Opdivo?” — 7 responses.
- “My oncologist mentioned Keytruda versus Opdivo… what are the key differences in how they’re positioned or prescribed?” — 7 responses.
- “When people say Keytruda is ‘more effective’… compared with Opdivo?” — 7 responses; the clearest direct competitive-perception signal.
- “What’s the difference between Keytruda and Tecentriq in terms of treatment choice?” — 7 responses.
5. Recommended actions
- Prioritize monitoring of Opdivo comparison demand, particularly the “more effective” question, which represents 7 responses and carries repeated superiority-language flags.
- Track Tecentriq as a secondary comparator; it appears in one explicit question but currently shows no evidence of rising share.
- Validate competitor tagging before next briefing. The zero raw counts conflict with competitor names in four questions and multiple excerpts, limiting confidence in share and mover conclusions.
- Continue routine monitoring rather than declaring a competitive shift. Current evidence supports stable, noncommittal comparative framing—not a demonstrated competitor move.